This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

Dosing & Half-LifeClinical Study DataSafety InformationSupport and ResourcesVideosMaterialsTherapy Management Strategies in Clinical PracticeBy Your Side™ App

The content of this website has been produced in line with the INLYTA® (axitinib) Summary of Product Characteristics for Great Britain. 
Prescribing Information for INLYTA® (axitinib) click here.  Prescribing Information for SUTENT® (sunitinib malate) click here. Adverse event reporting information can be found at the bottom of the page.

INLYTA® (axitinib) has a flexible dosing regimen and short half-life that could help you manage some adverse reactions1

The recommended starting dose is 5 mg twice daily, given orally.1

Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs that cannot be managed by concomitant medicinal products or dose adjustments.

If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time.

INLYTA® is available in 1 mg, 3 mg, 5 mg and 7 mg film-coated tablets to help dose adjustment.1

Flexible dosing regimen

The dose of INLYTA® can be titrated: increased in the absence of adverse events (AEs) or decreased in the presence of AEs.1

Patients who tolerate the starting dose of 5 mg twice daily with no adverse reactions >grade 2 for 2 consecutive weeks may have their dose increased to 7 mg twice daily unless the patient's blood pressure is >150/90 mmHg, or the patient is receiving antihypertensive treatment.1

​​Subsequently, using the same criteria, patients who tolerate a dose of 7 mg twice daily may have their dose increased to a maximum of 10 mg twice daily.1

Conversely, if adverse reactions develop, the dose may be reduced to 3 mg twice daily and then to 2 mg twice daily if needed.1

If a strong CYP3A4/5 inhibitor must be co-administered, a dose decrease from 5 mg BID to 2 mg BID is recommended. If a strong CYP3A4/5 inducer must be co-administered, a gradual dose increase is recommended and patients should be monitored for toxicities.1 However, it is preferable to select alternative medicines with no or minimal interaction potential as these dose adjustments have not been studied in patients receiving strong CYP3A4/5 inhibitors or inducers.

Short half-life

The half-life of INLYTA® is between 2.5 and 6.1 hours1

A short half-life could potentially lead to a relatively quick resolution of

some adverse reactions following a temporary treatment break (discontinuation) of 2 to 3 days.2
 

Once any adverse reactions subside, treatment with INLYTA® can be

restarted, if necessary at a reduced dose.2

Watch a short 2 minute video on INLYTA® dosing and half-life below:

Indication

INLYTA® is indicated for the treatment of adult patients with advanced renal cell carcinoma (aRCC) after failure of prior treatment with sunitinib or a cytokine.1​​​​​​​

Abbreviations:
AE : adverse event, BID : twice daily

References:

INLYTA® Summary of Product Characteristics for Great Britain click here. INLYTA®  Summary of Product Characteristics for Northern Ireland click here.

Schmidinger M, et al. Future Oncol 2018;14:861–875.

PP-INL-GBR-0959 July 2023

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​